Institut Bergonié

Bordeaux, France

55 recruiting

Showing 120 of 73 trials

Recruiting
Phase 3

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Metastatic Hormone Sensitive Prostate Cancer
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD320 enrolled56 locationsNCT07333066
Recruiting
Phase 3

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation260 enrolled48 locationsNCT06006117
Recruiting
Phase 3

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Colorectal, Cancer
Canadian Cancer Trials Group834 enrolled55 locationsNCT07152821
Recruiting
Phase 2

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

Neuroendocrine TumorsProgressive DiseaseIntestinal Well Differentiated Endocrine Tumor
Institut du Cancer de Montpellier - Val d'Aurelle146 enrolled28 locationsNCT04954820
Recruiting
Not Applicable

Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.

Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle108 enrolled7 locationsNCT04457895
Recruiting
Phase 1Phase 2

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Metastatic Castration-Resistant Prostatic Cancer
T.O.A.D. Oncology SA180 enrolled7 locationsNCT07258407
Recruiting

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Metastatic Breast Cancer
UNICANCER42,000 enrolled20 locationsNCT03275311
Recruiting

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Lung Cancer
UNICANCER75,000 enrolled21 locationsNCT03848052
Recruiting
Not Applicable

COsegregation of VARiants in Panel of Genes

Genetic PredispositionGene Mutation-Related Cancer
Institut Curie11,000 enrolled62 locationsNCT01689584
Recruiting
Phase 3

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled35 locationsNCT05581121
Recruiting
Phase 2Phase 3

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Solid Cancer
Daiichi Sankyo860 enrolled146 locationsNCT06161025
Recruiting
Phase 3

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation290 enrolled42 locationsNCT06284317
Recruiting
Phase 1Phase 2

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Advanced Solid Tumors
Domain Therapeutics Australia Pty Ltd125 enrolled9 locationsNCT06819735
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Breast Cancer
Pfizer400 enrolled202 locationsNCT07062965
Recruiting
Phase 2

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Unresectable Gastrointestinal Stromal Tumor (GIST)Locally Advanced Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal Tumor
Centre Leon Berard110 enrolled13 locationsNCT05152472
Recruiting
Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Malignant Solid Tumor
Centre Leon Berard455 enrolled10 locationsNCT04116541
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting

Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

Chronic Lymphocytic LeukemiaBTK Degraders
Nantes University Hospital60 enrolled14 locationsNCT07099443
Recruiting
Phase 3

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Breast Carcinoma
Institut Curie300 enrolled21 locationsNCT06195709
Recruiting
Phase 3

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Leiomyosarcoma
PharmaMar450 enrolled97 locationsNCT06088290